Kalpna Kay Durairaj, MD, FACS
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Kalpna Kay Durairaj, MD, FACS sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
Kalpna Kay Durairaj, MD, FACS: 3 sponsored US clinical trials, 1 recruiting.
Kalpna Kay Durairaj, MD, FACS sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Volume Loss (Soft Tissue Ptosis or Atrophy ), with 1 trials.
Upper-quartile sponsor footprint
Kalpna Kay Durairaj, MD, FACS sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
3 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Kalpna Kay Durairaj, MD, FACS pipeline
1 recruiting of 3 indexed (33% open); 2 completed (67%).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Volume Loss (Soft Tissue Ptosis or Atrophy ) (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Kalpna Kay Durairaj, MD, FACS: open-pipeline peers nationwide
Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Kalpna Kay Durairaj, MD, FACS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 trials (± recruiting share)
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Kalpna Kay Durairaj, MD, FACS page
3 registered trials is a research-attention snapshot, not an endorsement of Kalpna Kay Durairaj, MD, FACS or any single study.
- 1 of Kalpna Kay Durairaj, MD, FACS's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Volume Loss (Soft Tissue Ptosis or Atrophy ) is the condition Kalpna Kay Durairaj, MD, FACS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Volume Loss (Soft Tissue Ptosis or Atrophy ) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Kalpna Kay Durairaj, MD, FACS pipeline card: 3 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.